Compare TG Therapeutics Inc (TGTX) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Vale SA — how do they compare? TG Therapeutics Inc trades at $49.72 (market cap $7.64B), while Vale SA trades at $14.47 (market cap $61.97B). The key difference: Vale SA is far larger — about 8.1× TG Therapeutics Inc's market cap, and Vale SA pays a 8.35% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | VALE | |
|---|---|---|
Market Cap | $7.64B | $61.97B |
Sector | Health | Basic Materials |
52-Week High | $59.06 | $17.82 |
52-Week Low | $26.94 | $9.71 |
Enterprise Value | $7.84B | $78.22B |
Dividend Yield | — | 8.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TGTX trades at $50.26, up 2.24% in the last session, with a bearish technical signal from moving averages despite neutral oscillators. Recent Q2 2026 earnings missed estimates at $0.05 per share versus $0.3057 expected, though revenue surged to $240 million, driven by strong BRIUMVI sales growth of 64% year-over-year. The company raised 2026 revenue guidance to $950 million, reflecting robust demand for its multiple sclerosis treatment.
The outlook is mixed: strong revenue growth and a high analyst buy consensus (84.62%) support upside to the $63.75 price target, but earnings misses, a high EV/EBITDA of 56.26, and a shareholder investigation into fiduciary breaches pose risks. Investors should weigh the growth potential against execution and regulatory uncertainties.
VALE trades at $14.49, down 2.72% with a bearish technical outlook. Recent earnings missed expectations for three consecutive quarters, with Q3 2026 results pending. The company maintains strong cash flow generation ($8.8B operating cash flow in 2025) and a 5.11% net margin, though profitability has declined from 2022 peaks. Analyst consensus is mixed with 38% Buy ratings and a $16.79 price target, representing 16% upside potential.
VALE offers value with reasonable valuations (P/E 28.6, P/B 1.6) and dividend yield, but faces headwinds from rising costs and earnings volatility. The stock's near-term trajectory depends on Q3 earnings delivery and copper segment execution. Key risks include commodity price sensitivity and operational challenges in base metals expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
